戒烟干预对宫颈上皮内瘤变或宫颈癌生存者的疗效:一项随机对照试验
这项随机对照试验纳入202名有宫颈上皮内瘤变或宫颈癌病史且目前吸烟的女性,比较动机与问题解决(MAPS)干预与标准治疗(ST)的戒烟效果。主要结局为18个月时自报7天时点戒烟率,MAPS组14.2%对ST组12.9%,无显著差异(P=.79);但12个月时MAPS组戒烟率显著高于ST组(26.4%对11.9%,P=.017;估计OR 2.60,95%CI 1.19至5.89)。
要点
- 18个月时MAPS组与ST组自报7天时点戒烟率无显著差异(14.2%对12.9%,P=.79)。
- 12个月时MAPS组戒烟率显著高于ST组(26.4%对11.9%,P=.017;估计OR 2.60,95%CI 1.19至5.89)。
- MAPS组18个月戒烟率下降至与对照组相当,疗效不再显著。
核心结论
- MAPS在12个月时使宫颈上皮内瘤变和宫颈癌生存者的戒烟率增加超过两倍。
- 在18个月时,MAPS组戒烟率下降至与对照组相当,疗效不再显著。
研究设计与样本
- 随机对照试验,纳入202名有宫颈上皮内瘤变或宫颈癌病史、年龄18岁及以上、说英语或西班牙语、目前吸烟(终生至少100支香烟且过去30天内有吸烟)的女性。
- 参与者在俄克拉何马城诊所及全国在线招募,随机分配至标准治疗(ST)或MAPS。
- ST包括反复转介至戒烟热线、自助材料及联合尼古丁替代疗法(贴片加含片);MAPS包括全部ST内容加最多6次主动电话咨询,为期12个月。
- 主要结局为18个月时自报7天时点戒烟率,次要结局包括3、6、12个月戒烟率及生化确认戒烟。
主要发现
- 18个月时MAPS组与ST组自报7天时点戒烟率无显著差异(14.2%对12.9%,P=.79)。
- 存在显著的组别×评估时间交互作用(P=.015)。
- 12个月时MAPS组戒烟率显著高于ST组(26.4%对11.9%,P=.017;估计OR 2.60,95%CI 1.19至5.89)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Women who smoke and have a history of cervical intraepithelial neoplasia (CIN) or cervical cancer represent a vulnerable subgroup at elevated risk for recurrence, poorer cancer treatment outcomes, and decreased quality of life. The purpose of this study was to evaluate the long-term efficacy of Motivation And Problem Solving (MAPS), a novel treatment well-suited to meeting the smoking cessation needs of this population. METHODS: Women who were with a history of CIN or cervical cancer, age 18 years and older, spoke English or Spanish, and reported current smoking (≥100 lifetime cigarettes plus any smoking in the past 30 days) were eligible. Participants (N = 202) were recruited in clinic in Oklahoma City and online nationally and randomly assigned to (1) standard treatment (ST) or (2) MAPS. ST consisted of repeated referrals to a tobacco cessation quitline, self-help materials, and combination nicotine replacement therapy (patch plus lozenge). MAPS comprised all ST components plus up to six proactive telephone counseling sessions over 12 months. Logistic regression and generalized estimating equations evaluated the intervention. The primary outcome was self-reported 7-day point prevalence abstinence from tobacco at 18 months, with abstinence at 3, 6, and 12 months and biochemically confirmed abstinence as secondary outcomes. RESULTS: There was no significant effect for MAPS over ST at 18 months (14.2% v 12.9%, P = .79). However, there was a significant condition × assessment interaction (P = .015). Follow-up analyses found that MAPS (v ST) abstinence rates were significantly greater at 12 months (26.4% v 11.9%, P = .017; estimated OR, 2.60; 95% CI, 1.19 to 5.89). CONCLUSION: MAPS led to a greater than two-fold increase in smoking abstinence among survivors of CIN and cervical cancer at 12 months. At 18 months, abstinence in MAPS declined to match the control condition and the treatment effect was no longer significant.
引用
- Vidrine JI, Sutton SK, Wetter DW, et al. Efficacy of a Smoking Cessation Intervention for Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer: A Randomized Controlled Trial. J Clin Oncol. 2023. PMID: 36921237. doi:10.1200/JCO.22.01228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。